It really is concluded that EAM-2201 has the likely to result in in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is evaluated in pooled human liver microsomes. Thus, we conclude that fitting only to stable period Qualities, as is completed in most potential development treatments,